NeoGenomics (NEO) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
NeoGenomics Reports 27% Revenue Growth Driven by Strong Volume Gains and PathLogic Acquisition
April 28, 2015 7:00 AM EDTFT. MYERS, Fla., April 28, 2015 /PRNewswire/ --Â NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services today reported its results for the first quarter of 2015.
First Quarter 2015 Highlights:
Consolidated revenue growth of 27% Base(1) test volume growth of 28% Improvement in base average cost per test of 3.5% Adjusted EBITDA(2) of $1.5 millionRevenue for the first quarter was $23.0 million, a 27% increase over first quarter 2014 revenue. The PathLogic acquisition accounted for $2.3 million of revenue or 13% of this... More
